Poolbeg Pharma launches AI programme with Eurofins Genomics

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has signed a strategic collaboration agreement with a Nasdaq-listed biopharma company for the development of an optimised oral

Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the development of an optimised oral drug

The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While the pharmaceutical industry scrambled for vaccines

Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition. Poolbeg said that it will

Organoids – living, 3D multicellular models of human organs – could revolutionize early research and discovery of new medicines. Because organoids mirror human biology more closely than animal models like mice and rats, they are ideal

The pharmaceutical industry has long been at the forefront of scientific innovation, driving advancements in medicine that aim to improve the quality of human health and lifespan. The race to develop vaccines and treatments for COVID-19

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

In the swirling world of technological innovation, Artificial Intelligence has carved out a distinctive niche. It’s causing ripples of change across multiple sectors, but perhaps none more so than healthcare. From groundbreaking diagnostics to the fine

Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency.

Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a

Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington –

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST